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Abstract
Background: Snakebite is a significant cause of death and disability in subsistent farming populations of sub-Saharan Africa.
Antivenom is the most effective treatment of envenoming and is manufactured from IgG of venom-immunised horses/
sheep but, because of complex fiscal reasons, there is a paucity of antivenom in sub-Saharan Africa. To address the plight of
thousands of snakebite victims in savannah Nigeria, the EchiTAb Study Group organised the production, testing and
delivery of antivenoms designed to treat envenoming by the most medically-important snakes in the region. The Echis saw-
scaled vipers have a wide African distribution and medical importance. In an effort to maximise the clinical utility of scarce
antivenom resources in Africa, we aimed to ascertain, at the pre-clinical level, to what extent the E. ocellatus-specific
EchiTAbG antivenom, which was designed specifically for Nigeria, neutralised the lethal activity of venom from two other
African species, E. pyramidum leakeyi and E. coloratus.
Methodology/Principal Findings: Despite apparently quite distinctive venom protein profiles, we observed extensive cross-
species similarity in the immuno-reactivity profiles of Echis species-specific antisera. Using WHO standard pre-clinical in vivo
tests, we determined that the monospecific EchiTAbG antivenom was as effective at neutralising the venom-induced lethal
effects of E. pyramidum leakeyi and E. coloratus as it was against E. ocellatus venom. Under the restricted conditions of this
assay, the antivenom was ineffective against the lethal effects of venom from the non-African Echis species, E. carinatus
sochureki.
Conclusions/Significance: Using WHO-recommended pre-clinical tests we have demonstrated that the new anti-E. ocellatus
monospecific antivenom EchiTAbG, developed in response to the considerable snakebite-induced mortality and morbidity
in Nigeria, neutralised the lethal effects of venoms from Echis species representing each taxonomic group of this genus in
Africa. This suggests that this monospecific antivenom has potential to treat envenoming by most, perhaps all, African Echis
species.
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Introduction
The rural communities of sub-Saharan Africa suffer the
multiple burdens of low economic status, inadequate access to
effective health care and the debilitating effects of numerous
infectious and parasitic diseases. The subsistence agriculture
livelihood, non-mechanised farming techniques, remote locations
and proximity of homes to farms/grain stores all contribute to the
fact that these communities also suffer a disproportionally high
snakebite mortality rate [1]. Extrapolations from recent global
snakebite incidence and mortality data [2] reveal that while the
percent lethality of snakebite in Latin America is 1.8% (2,300
deaths; 129,000 incidences) it is 7.6% in sub-Saharan Africa
(32,000 deaths; 420,000 incidences). These rather crude data-
extrapolations are presented simply to emphasise the point that
circumstances in sub-Saharan Africa make snakebite a more life-
threatening event than elsewhere.
While socioeconomic issues at the community level and per
capita government expenditure on health at the national level
certainly contribute to this disparity [1], an important additional
explanation is the relative scarcity of antivenom in Africa [3–6].
IgG antivenom is the most effective treatment of systemic snake
envenoming. However, its manufacture from sera of venom-
immunised horses or sheep means that antivenom is a more
expensive therapy (US$100/vial in S Africa) than many other non-
subsidised medicines administered in sub-Saharan Africa. As
described in the cited and related literature, the (i) relatively high
cost of antivenom, (ii) its restricted efficacy to the species of snake
whose venom was used in its manufacture and (iii) factors relating
to commercial manufacturing incentives have all combined to
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therefore a compelling need to maximise the clinical utility of
effective antivenoms that are becoming available in the region.
In response to the crisis in antivenom supply affecting Nigeria,
the EchiTAb Study Group (a collaboration between the Nigerian
Federal Ministry of Health, antivenom manufacturers in Costa
Rica (Instituto Clodomiro Picado) and Wales (MicroPharm Ltd)
and academics in the Liverpool School of Tropical Medicine and
University of Oxford) has organised the production, pre-clinical
testing [7,8], human efficacy testing [9] and delivery of two new
antivenoms for Nigeria, EchiTAb-Plus-ICP and EchiTAbG.
The saw-scaled viper, Echis ocellatus, is responsible for most
snakebite-deaths in Nigeria [10–12]; the other medically-impor-
tant snakes are the puff adder, Bitis arietans, and the spitting cobra,
Naja nigricollis [13,14]. EchiTAb-Plus-ICP is a new equine
polyspecific IgG antivenom developed in Costa Rica to treat
envenoming by all three snake species [7]. In view of the very high
number of E. ocellatus bites in Nigeria and the severe haemor-
rhaging and incoagulable bleeding experienced by systemically
envenomed victims, an additional ovine IgG antivenom, Echi-
TAbG (MicroPharm Ltd) was manufactured in Wales for the
treatment of E. ocellatus envenoming and has been registered (A6-
0078) by the Nigerian medicines authority, NAFDAC. Since E.
ocellatus is widely distributed across the West African savannah
(Figure 1), EchiTAbG offers considerable therapeutic promise in
many countries in the region. With the intent of maximising the
clinical contribution of this new antivenom and cognisant that (i)
other Echis species represent public health concerns in East (E.
pyramidum) and North-East (E. coloratus) Africa (Figure 1) and (ii)
that their venom protein family composition is not dissimilar to E.
ocellatus [15], the objective of this study was to examine the pre-
clinical intra-generic venom-neutralising efficacy of EchiTAbG.
Author Summary
Snakebite is principally a health concern of rural poor
communities. The high snakebite risk of subsistence
farming and paucity of effective antivenoms in sub-
Saharan Africa means that many communities remain
unacceptably vulnerable to snakebite mortality and
morbidity. There is therefore a compelling need to
maximise the utility of the snakebite therapies that are
available. To address Nigeria’s severe snakebite problem,
the government funded a collaboration of ministry
officials, antivenom manufacturers and academics (the
EchiTAb Study Group) to produce, test and deliver
antivenom. Accordingly, we prepared EchiTAbG, an anti-
venom specific for envenoming by the saw-scaled viper (E.
ocellatus) which is responsible for 80% of snakebite deaths
in Nigeria. Since E. ocellatus is widely distributed across the
West African savannah, EchiTAbG offers considerable
therapeutic promise in many countries in the region. Since
other Echis species represent public health concerns
elsewhere in Africa, the objective of this study was to
examine the pre-clinical intra-generic venom-neutralising
efficacy of EchiTAbG. Our results suggest that EchiTAbG
(Nigeria registration: A6-0078) has pan-African efficacy
against Echis envenoming indicating that costly invest-
ment in region-specific antivenoms therefore may not be
required. This represents an important progression to
minimise development costs and maximise the delivery of
snakebite therapy for the continent.
Figure 1. Distribution of four Echis species in Africa and the Middle East. Key: E. ocellatus – blue, E. pyramidum – red, E. coloratus – green, E.
carinatus – purple. Distributions mapped according to the WHO venomous snake distribution database and a recent study of the genus Echis [16,35].
doi:10.1371/journal.pntd.0000851.g001
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To achieve a more complete understanding of the immunology
underpinning the cross-specific venom neutralising potential of
EchiTAbG, we performed a series of assays to determine the IgG
titre, specificity and relative avidity of sera raised in sheep
immunised with venom from species representing each taxonomic
group of the Echis genus in Africa [16] as follows: (i) E. pyramidum
leakeyi (Kenya) representing the pyramidum complex which includes
E. leucogaster and E. p. pyramidum, (ii) E. coloratus (Egypt) representing
this species and E. omanensis, (iii) E. ocellatus representing this species
and E. jogeri. To assess the geographic limitation of the exercise we
included venom from a non-African saw-scaled viper (E. carinatus
sochureki, United Arab Emirates) in all the experiments, including
provision of species-specific antisera.
Snakes and venom extraction
Snakes were maintained in the Herpetarium at the Liverpool
School of Tropical Medicine. Venom was extracted from wild-
caught specimens of E. ocellatus (Nigeria), E. coloratus (Egypt), E. p.
leakeyi (Kenya) and E. c. sochureki (UAE) on several occasions,
pooled, frozen, lyophilised and stored at 4uC prior to reconstitu-
tion in phosphate-buffered saline (PBS).
Immunisation and antiserum production
Antisera were generated against venom from E. p. leakeyi, E.
coloratus and E. c. sochureki using protocols identical to that used in
the production of the E. ocellatus-specific antivenom, EchiTAbG.
Six sheep (two per venom) were initially immunised with 0.5mg of
venom emulsified with Freund’s Complete Adjuvant followed by
boosting immunisations of 1.0mg of venom emulsified with
Freund’s Incomplete Adjuvant every 28 days. To maximise
seroconversion, venom immunisations were administered subcu-
taneously in six sites close to the major draining lymph nodes in
the neck and groin. Blood samples were taken 14 days after
immunisation.
Once the anti-venom IgG had reached a plateau (16 weeks,
personal communication, MicroPharm Ltd) one litre of blood was
taken, allowed to clot, centrifuged and the sera stored at 220uC.
IgG was extracted by the addition of caprylic acid (Sigma, UK) to
a final concentration of 5% and stirring vigorously for two hours to
precipitate non-IgG proteins. The suspension was centrifuged at
13,000 rpm (in a microcentrifuge) for 60 min and the supernatant
IgG dialysed with three changes of 20 mM sodium phosphate
buffer (pH 7.4). All the IgG preparations were formulated to the
same concentration, 30mg/ml in PBS, and stored at 220uC. IgG
generated against E. ocellatus venom and the E. ocellatus antivenom
EchiTAbG were obtained from MicroPharm Ltd.
Note: to avoid possible confusion between the antivenoms
resulting from commercial manufacture and the anti-Echis species
IgG antivenoms prepared in our laboratory – the latter have been
termed IgG antisera.
Immunological assays
a) End Point Titration (EPT) ELISA. Ninety six (96) well
ELISA plates (Nunc) were coated with 100ng of venom (a separate
plate for each Echis species) prepared in carbonate buffer, pH 9.6
and the plates incubated at 4uC overnight. Plates were washed
after each stage, using 6 changes of TBST (0.01 M Tris-HCl,
pH 8.5; 0.15 M NaCl; 1% Tween 20). Next, the plates were
incubated at room temperature (RT) for 3 hours with 5% non-fat
milk (diluted with TBST) to ‘block’ non-specific reactivity. The
plates were then washed and incubated (in duplicate) with each of
the four Echis species-specific IgG antisera, at an initial dilution of
1:100 followed by 1:5 serial dilutions and incubated overnight at
4uC. The plates were washed and then incubated in horseradish
peroxidise-conjugated goat anti-sheep IgG (1:1000; Sigma, UK)
for 3 hours at RT. The results were visualized by addition of
substrate (0.2% 2,2/-azino-bis (2-ethylbenzthiazoline-6-sulphonic
acid) in citrate buffer, pH 4.0 containing 0.015% hydrogen
peroxide (Sigma, UK) and optical density (OD) measured at
405nm. The titre is described as the dilution at which absorbance
was greater than that of the negative control (IgG from non-
immunised sheep) plus 2 standard deviations.
b) Relative avidity ELISA. This assay was performed as
above except that the IgG antisera were diluted to a single
concentration of 1:10,000, incubated overnight at 4uC, washed
with TBST and the chaotrope, ammonium thiocyanate, added to
the wells in a range of concentrations (0–8 M) for 15 minutes.
Plates were washed, and all subsequent steps were the same as the
End Point Titration ELISA. Relative avidity was determined as
the percentage reduction in ELISA OD reading (measured at
405nm) between the maximum (8 M) and minimum (0 M)
concentrations of ammonium thiocyanate.
c) SDS-PAGE and immunoblotting. The lyophilised Echis
species venoms were reconstituted to 1mg/ml in reduced protein
loading buffer and boiled for ten minutes. Seven mg of venom,
together with molecular weight marker (Broad range molecular
weight protein markers, Promega) was added to a 15% SDS-
PAGE gel and fractionated under 200 volts and the resultant
proteins visualised by staining with Coomassie Blue R-250.
Immunoblottingwascarriedoutinthesamewayexceptthatafter
electrophoresis, the gels were electro-blotted onto 0.45mm nitrocel-
lulose membranes using the manufacturer’s protocols (Bio-Rad,
UK). Following confirmation of successful protein transfer by
reversible Ponceau S staining, the membranes were incubated
overnight inblocking buffer(5%non-fat milk inTBST),followed by
six washes of TBST over 90 minutes and incubation overnight with
primaryantibodies (theE.ocellatus-,E.p.leakeyi-,E.coloratus-a n dE. c.
sochureki-specific IgG) diluted 1:5,000 in blocking buffer. Blots were
washed as above, then incubated for 2 hours with horseradish
peroxidise-conjugated donkey anti-sheep secondary antibody
(1:2,000 dilution) before a final wash with TBST and visualisation
after the addition of DAB substrate (50 mg 3,3-diaminobenzidine,
100 ml PBS and 0.024% hydrogen peroxide; Sigma, UK).
d) Small scale affinity purification. To assess the cross-
reactivity of the four Echis species-specific IgG antisera to venoms
under native conditions (and conditions distinct to that of the
ELISA assays), we prepared small scale affinity columns for each
of the venoms. 1g of CNBr-activated 4 Fast Flow Sepharose (GE
Healthcare, UK) was swollen, washed with 1mM HCl, transferred
to a 3.5ml column (Bio-Rad, UK) and washed twice with 0.1M
sodium hydrogen carbonate pH 8.3. Five mg of venom (1mg/ml
0.1M sodium hydrogen carbonate pH 8.3 solution) was coupled
with the Sepharose by end-over-end mixing at 4uC overnight.
Columns were drained and active groups blocked by end-over-end
mixing for 2 hours with 1M Ethanolamine-Cl pH 9.0, washed in
washing buffer (0.1M sodium phosphate pH 7.5 containing 0.5M
NaCl) and eluted (0.1M glycine pH 2.5 containing 0.1M HCl)
before storage at 4uC. Columns were equilibrated at RT and
washed in washing buffer before 3mg of the species-specific IgG
antisera (1mg/ml in washing buffer) was added to the column and
mixed overnight. Columns were subsequently washed and eluted.
The eluate was concentrated using 5 kDa cut-off Vivaspin
columns (Sartorius Stedim Biotech, UK) and quantified using a
LD1000 series NanoDrop spectrophotometer (Thermo Scientific,
USA). The results were calculated as a percent of the 3mg of
species-specific IgG added to each column.
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All animal experimentation was conducted using protocols
approved by the University of Liverpool Animal Welfare
Committee and performed under licenced approval of the UK
Home Office.
a) Venom lethality. As an essential prerequisite to assessing
antivenom efficacy, we determined the median lethal dose (LD50)
for each of the four Echis venoms in mice using WHO-
recommended protocols [17] refined to reduce the duration of
the procedure [18]. Briefly, groups of five male CD-1 mice (18–
20g) received an intravenous (iv) tail injection of varying doses of
venom in 100ml PBS and, 7 hours later, the number of surviving
mice in each group was recorded. The venom LD50 (the amount
of venom that kills 50% of the injected mice) and 95% confidence
limits of each Echis species was calculated using probit analysis
[19].
b) Antivenom neutralisation of venom lethality. To
compare the effectiveness of EchiTAbG to neutralise the lethal
effects of each of the Echis species venoms, we used the median
effective dose (ED50) assay; a WHO-recommended test for
determining the least amount of antivenom required to prevent
death in 50% of mice injected with five venom LD50s. Using a
previously described protocol [18], various doses of EchiTAbG
antivenom were mixed with 5 venom LD50s and the final volume
made up to 200ml with PBS and the mixture incubated at 37uC for
30 minutes. The mixture was iv injected into the tail vein of groups
of 5 CD-1 mice and, 7 hours later, the number of surviving mice in
each group was recorded. The median effective dose (ED50)a n d
95% confidence limits were calculated using probit analysis [19].
The 7 hour time frame for the LD50 and ED50 assays was used
instead of the more conventional 24 hour period as a result of
numerous earlier assays which revealed that over 98% mice
succumbed to E. ocellatus envenoming within 7 hours of injecting
the venom or venom/antivenom mixture (data not shown). These
observations, with this venom, permitted us to make this humane
reduction in the duration of the experiments without risking
invalidating the results.
Results
Immunological profiles of the Echis species-specific IgG
antisera
The reduced SDS-PAGE profiles reveal intra-generic variation
in molecular mass and quantitative representation of the venom
proteins present in the four Echis venoms (Figure 2A). However,
immunoblotting of the four venoms with each of the four Echis
species-specific IgG antisera demonstrated that the intensity of
immunoreactivity of each IgG antiserum to proteins of the
homologous venom was matched by that to the three heterologous
venoms (Figure 2B–E). Indeed, such was the intensity of the cross-
species IgG immunoreactivity that we were unable to detect any
protein in the SDS-PAGE venom profiles that was not reactive
with each of the four Echis species-specific IgG antisera.
Furthermore, the immunoblots revealed the existence of more
venom proteins than was apparent from the SDS-PAGE. We
interpret this analysis as illustrating that while intra-generic
differences in the size of the venom proteins exist, these proteins
were likely to be size-variants of the same protein families.
Figure 2. Echis species-specific IgG antisera exhibit extensive cross-specific venom protein reactivity. The venom proteins of E. ocellatus
(E.o), E. p. leakeyi (E.p.l), E. coloratus (E.c) and E. c. sochureki (E.c.s) visualised using reduced SDS-PAGE (A), after immunoblotting, showed extensive
cross-specific reactivity with IgG antisera specific to E. ocellatus (B), E. p. leakeyi (C), E. coloratus (D) E. c. sochureki (E). The sera were diluted 1:5,000 and
7mg of each venom was used in all gels.
doi:10.1371/journal.pntd.0000851.g002
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EPT ELISA assay to determine the IgG titre of each of the four
Echis species-specific IgG antisera to each Echis venom (Figure 3A–
D). The overall plateau and then decline of IgG titre after
successive IgG dilution was strikingly similar for each of the IgG
antisera; as reflected in the assigned EPT IgG titres (Table 1). The
slightly slower decline of the E. coloratus venom-antisera profiles
against each of the venoms (except the E. c. sochureki venom,
Figure 3D) suggested that E. coloratus venom is perhaps more
immunogenic than the other Echis venoms. Similarly, because the
E. p. leakeyi IgG antisera showed the most rapid decline in IgG titre
against its homologous and the heterologous venoms, it could be
surmised that E. p. leakeyi venom is the least immunogenic.
However, these differences were minor and we therefore caution
against assigning much immunological significance to these
observations.
Considerable intra-generic immunological cross-reactivity was
noted from the immunoblotting and ELISA assay when the
venoms were in ‘reduced’ or ‘native’ states (respectively). We next
wished to examine this immunological cross-reactivity using a
technology also using ‘native’ venoms but in a manner that would
likely present the venom proteins to the IgG in a different
configuration - and perhaps better reflecting the in vivo situation -
than that achieved in the ELISA assay. We therefore prepared
small scale CnBr-activated venom-affinity columns for each Echis
venom and measured the amount of each Echis species-specific
IgG that remained bound to the column after extensive washing of
the column (Table 2). This new assay to measure venom-
antivenom interactions revealed, in each case, that highest binding
occurred between the homologous combination of venom and IgG
antisera. This was the first assay to indicate that there are intra-
generic differences in Echis venoms with immunological signifi-
cance.
To determine the strength of venom-antivenom binding in the
presence of ammonium thyiocyanate (which disrupts protein-
protein interactions), we used the Relative Avidity ELISA assay to
examine the titre of the four Echis species-specific IgG antisera to
each of the venoms in the presence of increasing amounts of the
chaotrope (Figure 4). Consistent with the results of the small scale
Figure 3. Extensive cross-specific immunological reactivity between Echis venoms and Echis species-specific IgG antisera revealed
by End Point Titration ELISA. Venom from E. ocellatus (blue bars), E. p. leakeyi (red bars), E. coloratus (green bars) and E. c. sochureki (purple bars)
were incubated with serial dilutions (horizontal axis) of IgG antisera raised against E. ocellatus (A), E. p. leakeyi (B), E. coloratus (C) and E. c. sochureki (D)
and the optical density determined (vertical axis).
doi:10.1371/journal.pntd.0000851.g003
Table 1. The End Point Titre of each Echis species-specific IgG
antisera to each Echis venom.
Echis species-specific IgG antisera
Venom E. ocellatus E. p. leakeyi E. coloratus E. c. sochureki
E. ocellatus 1.56610
206 3.12610
205 1.56610
206 1.56610
206
E. p. leakeyi 1.56610
206 3.12610
205 1.56610
206 1.56610
206
E. coloratus 7.81610
206 1.56610
206 1.56610
206 1.56610
206
E. c. sochureki 1.56610
206 1.56610
206 1.56610
206 1.56610
206
Italicised values highlight homologous combinations of venom-IgG antisera.
doi:10.1371/journal.pntd.0000851.t001
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affected by the chaotrope, therefore exhibiting the strongest
binding, were between the homologous combinations of venom
and IgG antisera. The E. ocellatus IgG antisera exhibited the
strongest binding and the E. c. sochureki IgG antisera showed the
overall weakest binding to other Echis venoms (Figure 4).
Pre-clinical tests of venom lethality and venom-
neutralising efficacy of EchiTAbG
The lethal effects (expressed as LD50s) of the four Echis venoms
to mice, ranged from 9.81mg venom/mouse for E. coloratus to
15.10mg for E. c. sochureki. The 95% confidence limits indicate
there is no significant difference between the venom lethalities of
the four Echis species (Table 3).
Only slightly varying volumes of the E. ocellatus antivenom,
EchiTAbG, was required to completely neutralise venom-induced
lethality of the three African Echis species (E. ocellatus, E. p. leakeyi
and E. coloratus; Table 3). Perhaps surprisingly in light of results of
the small scale venom-affinity and Relative Avidity assays,
EchiTAbG was more effective against E. coloratus venom than
against its homologous venom, E. ocellatus. Importantly, Echi-
TAbG was ineffective at the maximal permitted volume of
antivenom (100ml) against the Asian species, E. c. sochureki.
We were concerned with the apparently conflicting observations
that although the E. c. sochureki venom exhibited the lowest toxicity
(highest LD50 result), EchiTAbG was unable to neutralise its
venom effects. We therefore performed an ED50 test with E. c.
sochureki venom and its homologous IgG antisera (Table 3); the
latter proving as effective against E. c. sochureki venom (54.42ml/
mouse) as EchiTAbG against E. ocellatus venom.
The efficacy of EchiTAbG against the lethal effects of E. ocellatus
venom noted in this study (an ED50 of 58ml antivenom/mouse:
1740mg antivenom/mouse) was substantially lower than that
recently reported for this antivenom-venom combination (ED50 of
8ml) in a separate study [8]. The E. ocellatus venom LD50 results
here and from the other study [8] are comparable and consistent
with other publications [18,20] indicating that the disparate ED50
results did not arise from batches of E. ocellatus venom with
different toxicities. We have repeated the ED50 experiment with
different batches of EchiTAbG antivenom and E. ocellatus venom
in published [18] and unpublished experiments (data not shown)
with results that confirm those obtained in this study.
The results of the ED50 assays demonstrate a lack of congruence
between the results of in vivo pre-clinical tests and immunological
assays. Notably, no single immunological assessment could be used
to predict the pre-clinical efficacy of EchiTAbG. Only the Relative
Avidity ELISA results indicated the potential ineffectiveness of
EchiTAbG against E. c. sochureki venom (Figure 4). We interpret
this as indicating that while all effective antivenoms require high
levels of IgG titre, specificity and avidity [18,21], these
immunological characteristics cannot be used to predict anti-
venom efficacy.
Discussion
Physicians throughout Africa are tasked with treating victims
suffering life-threatening effects of envenoming that include
systemic haemorrhage, coagulopathy, neurotoxicity and renal
failure. Identifying the snake species is often difficult - making it
problematic to select the most appropriate antivenom, which, in a
resource-poor setting, are scarce and expensive. The problem is
made more complex because the snake species responsible could
be any of the following a) viper species (the Echis saw-scaled vipers;
the puff adder, B. arietans; and several other Bitis species which,
although incidences are rare can be potentially lethal), b) elapid
species (the black-necked spitting cobra, Naja nigricollis; the
Egyptian cobra, N. haje; the Mozambique spitting cobra, N.
mossambica; the forest cobra, N. melanoleuca; species of the mamba
genus including the black mamba, Dendroaspis polylepis and green
mambas of East Africa, D. angusticeps and Central/West Africa, D.
jamesoni and D. viridis) and c) the colubrid Boomslang, Dispholidus
typus. Presumably in consideration of the above, the SAIMR
polyspecific antivenom manufactured in South Africa (South
African Vaccine Producer) includes venoms from many of the
above snakes in its venom-immunisation mixture.
The EchiTAb Study Group’s decision to manufacture an E.
ocellatus-specific antivenom and a E. ocellatus, B. arietans and N.
nigricollis polyspecific antivenom reflects the snakebite therapeutic
needs of Nigeria. Epidemiological studies had identified these
three species as being of greatest medical importance in the
country [11–14,22] and were the basis for deciding upon a
polyspecific antivenom – EchiTAb-Plus-ICP produced in Costa
Rica. The decision to manufacture an E. ocellatus-specific
antivenom (EchiTAbG produced in UK) was based on (i) the
unusually high E. ocellatus-bite incidence rate in Nigeria [11], (ii)
the 10–20% fatality rate of untreated victims of E. ocellatus
envenoming [10,23] and (iii) that the 20 minute blood clotting test
Table 2. Venom affinity-chromatography to measure the
binding strength of each Echis species-specific antisera to
each venom.
Echis species-specific IgG antisera
Venom
Column E. ocellatus E. p. leakeyi E. coloratus
E. c.
sochureki
E. ocellatus 10.23 5.12 6.77 7.51
E. p. leakeyi 8.32 8.02 6.95 7.53
E. coloratus 8.44 7.71 9.28 9.38
E. c. sochureki 8.11 4.95 6.90 11.12
The amount of IgG from each Echis species specific antisera that remained
bound to the Echis venom affinity chromatography column is displayed as a
percent of the 3 mg of each IgG added to the column. Italicised values
highlight homologous venom-antivenom results.
doi:10.1371/journal.pntd.0000851.t002
Figure 4. The Relative Avidity of each Echis species-specific IgG
antisera to each Echis venom. Results are expressed as the
percentage decline in ELISA optical density (405nm) from the control
(incubation with 0 M ammonium thiocyanate) to the treatment (8 M).
Boxed bars highlight homologous venom-antivenom results.
doi:10.1371/journal.pntd.0000851.g004
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from other West African venomous species – facilitating the
physicians antivenom-selection decision. Another consideration
was that the dose-efficacy of monospecific antivenoms is typically
greater than polyspecific antivenoms (the curative dose of
EchiTAbG is one vial and three vials for EchiTAb-Plus-ICP)
and thus monospecific antivenoms offer a more cost effective
treatment option – providing that the snake species can be
identified using either distinct symptomatology or species identi-
fication. The incidence of antivenom-induced adverse effects of
both the EchiTAb Study Group antivenoms is low [8], perhaps
because both are produced under sterile GMP conditions
employing caprylic acid to select IgG from sera/plasma.
EchiTAbG is now a registered medicine in Nigeria (A6-0078)
and EchiTAb-Plus-ICP is currently in the process of registration.
In addition to providing the Nigerian Federal Ministry of
Health with the monospecific EchiTAbG and polyspecific
EchiTAb-Plus-ICP antivenoms, the EchiTAb Study Group has
also provided ‘best-practice’ training of hospital physicians in (i)
the clinical use of these antivenoms, (ii) treatment of adverse effects
and (iii) surgical treatment of the tissue-necrotic effects of local
envenoming. Training was also given in the use of snake-
identification and symptomology of envenoming to assist in
making the most cost-effective and clinically-effective antivenom-
selection decisions. The EchiTAb Study Group also provided
ambulances to improve the speed of antivenom treatment of
envenomed victims in an effort to improve the clinical outcome.
The EchiTAb Study Group considered this multi-faceted
approach to snakebite treatment as the most effective means of
addressing the variant needs of snakebite victims in the region.
EchiTAbG is being provided free to patients in two hospitals in
Nigeria (Kaltungo, Gombe State and Zamko, Plateau) where
admitting 30 snakebite victims a day is not unusual, particularly in
the biannual rain seasons. While it is the intent of the EchiTAb
Study Group to expand the geographical delivery of its
antivenoms, the current scarcity of effective antivenom in the
region has resulted in victims undertaking long and expensive
journeys to attend these hospitals, with some victims reportedly
travelling from as far as Cameroon in the East and Niger in the
North-West (personal observation, AN and ND). These observa-
tions indicate the paucity of effective and affordable antivenom in
West Africa where snakebite, and particularly E. ocellatus,i sa
medical problem in most countries (Burkina Faso [26], Mali [27]
Co ˆte d’-Ivoire [28], Ghana [29], Benin [30], Niger [31] and
Cameroon [32]). EchiTAbG therefore offers a therapeutic benefit
in many countries other than Nigeria for which it was designed.
Since the East and North-East African Echis vipers are also a
public health concern, our objective was to determine, at the pre-
clinical level, whether the efficacy of EchiTAbG against E. ocellatus
could be extended to these other Echis species. Ideally, our pre-
clinical assays would have been conducted on venoms from all the
African Echis species but we could not justify the ethical and
financial costs of such a large number of mice. Therefore, based
upon the most comprehensive taxonomic study of the genus Echis
[16], we selected a single species from each of the four distinct
species complexes; (i) E. p. leakeyi (Kenya) as a representative of the
pyramidum complex which also includes E. leucogaster and E. p.
pyramidum, (ii) E. coloratus (Egypt) as a representative of this species
and E. omanensis, (iii) E. ocellatus as a representative of this species
and E. jogeri and (iv) E. c. sochureki (United Arab Emirates) as a
representative of the Asiatic carinatus complex. Our earlier work on
the venom gland transcriptomes of these representative Echis
species revealed considerable intra-generic differences in the
number of isoforms comprising the main Echis toxin groups (snake
venom metalloproteinases, phospholipases A2, serine proteases, C-
type lectins) [15]. However, each pathogenic toxin family was
represented in all the Echis species [15] – a result suggesting the
possibility that EchiTAbG would have cross-Echis species efficacy.
However, we were also aware of previous clinical failures of the
‘heterologous’ administration of Echis species-specific antivenoms
[33,34]. Consequently, and in line with WHO recommendations
[17], we performed here a series of immunological assays
examining the immunological venom cross reactivity of ovine
IgG raised against each representative Echis species. The results of
these assays, which were designed to measure IgG titre, specificity
and relative avidity to venoms in reduced and native states,
indicated a very considerable degree of immunological cross-
reactivity of each species-specific IgG antisera to each Echis
venom. However, EchiTAbG was ineffective in neutralising the in
vivo lethal effects of E. c. sochureki. This indicates that while these
immunological tests provide informative and comprehensive
immunological profiles of an antivenom, they can not yet replace
pre-clinical in vivo testing to indicate the efficacy of an antivenom.
The most important result of the study was that EchiTAbG
neutralises the lethal effects of venom from East and North-East
African Echis species (E. p. leakeyi and E. coloratus) with an efficacy
equal to that it shows against E. ocellatus from West Africa. A recent
study reports a similar potential for the other EchiTAb Study
Table 3. Venom lethality and venom-neutralising efficacy of (A) EchiTAbG and (B) the E.c. sochureki IgG antisera.
A) LD50 (mg/mouse) ED50 (ml/mouse)
Venom EchiTAbG
E. ocellatus 12.43 (9.00–20.45) 58.46 (35.32–90.92)
E. p. leakeyi 13.55 (8.98–38.33) 64.87 (23.86–129.65)
E. coloratus 9.81 (6.06–19.25) 44.25 (21.90–58.29)
E. c. sochureki 15.10 (6.49–19.70) NE
B) LD50 (mg/mouse) ED50 (ml/mouse)
Venom E. c. sochureki IgG antisera
E. c. sochureki 15.10 (6.49–19.70) 54.42 (43.93–58.33)
The venom lethality for each Echis species is expressed as the Median Lethal Dose (LD50). The venom-neutralising efficacy (ED50) was determined for (A) EchiTAbG
against venom from all the Echis species and (B) for the E. c. sochureki IgG antisera against E. c. sochureki venom. 95% confidence limits are displayed in parentheses.
NE=Not effective.
doi:10.1371/journal.pntd.0000851.t003
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clinical results require verification in human clinical trials, they do
indicate a wider than intended application for both EchiTAbG
and EchiTAb-Plus-ICP. We believe this is vitally important to the
sustained delivery of these new antivenoms, developed to resolve a
crisis in antivenom supply to Nigeria, because their production is
now vulnerable to the same fiscal insecurities that caused the
antivenom crisis a decade ago. A greater market, through
geographical expansion, should permit the application of econo-
mies of scale that hopefully will, sequentially, reduce costs to the
purchasing ministries of health, increase demand and improve the
delivery of these urgently needed life-saving therapies.
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